Avalyn Pharma (AVLN) vs First Tracks Biotherapeutics (TRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Avalyn Pharma is the larger company by market cap ($1.13 billion vs $1.09 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVLN | TRAX |
|---|---|---|
| Share price | $25.53 | $30.59 |
| Market cap | $1.13B | $1.09B |
| 1-day change | +0.39% | -2.55% |
| EPS (TTM) | $-2.47 | $-4.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.17 | $49.91 |
| 52-week low | $24.15 | $14.72 |
| Distance from 52-week high | -36.45% | -38.71% |
| Average volume | 238.20K | 788.93K |
| Shares outstanding | 44.33M | 35.73M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
AVLN vs TRAX FAQ
Which is bigger, Avalyn Pharma or First Tracks Biotherapeutics?
Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.13B compared with $1.09B for First Tracks Biotherapeutics (TRAX).
Are Avalyn Pharma and First Tracks Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.